Vol - 25, Issue - 6
About the Journal
[This article belongs to Volume - 25, Issue - 6]
International Medical Journal
Journal ID : IMJ-07-06-2020-496
Total View : 294

Abstract : The world still suffering from COVID-19 infection that approaching 7.000.000 victim, however, there are no accurate data about the incidence ofCOVID-19 inpaediatric age group. Inthe last days of the precedingApril 2020, the British national health council announced a warning about the ‘increased number of children with multisystem inflammatory syndrome (MIS-C), who needed an intensive care’. These children had an overlapping symptoms of toxic shocksyndrome (TSS) and atypicalKawasaki disease (KD), with laboratory results could be or not, consistent with COVID-19 infection. All cases shared a common presentation of abdominal pain, gastro-intestinal symptoms and evidence of myocarditis, mortality has been reported. In the 15th of May 2020, the WHO published a scientific briefing for thediagnostic clinical criteria, and treatment outline for this emerging syndrome. Intravenous immune globulin, convalescence plasma, anticoagulants and biological agents are the main line of treatment. Our case is atwelve years old boy from Najaf, presented with fever, sore throat, without dyspnea but with nausea, drowsiness and marked gastrointestinal symptoms and proved to be positive for COVID-19. With his investigations, he fulfilled the criteria forthe diagnosis of Multisystem inflammatory syndrome in children (MIS-C). During early days of hospitalisation his condition deteriorated farther. He received the recommended therapy including steroids, convalescent plasma, anticoagulants, and later he required the biological agent that gave anexcellent and dramatic response, he discharged home well after few days

Our Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates